~," Interstitial irradiation is a promising treatment for malignant glioma. Longer than expected survival periods following treatment of recurrent tumor have led to the use of brachytherapy as an adjuvant treatment. The impact of patient selection on survival data was studied among candidates for this therapy. Consecutive, conventionally treated adults with newly diagnosed supratentorial tumors were identified retrospectively at a center where experience with glioma is population-based. Based on imaging and performance status, two surgeons and a radiation oncologist designated each patient as either eligible or ineligible for adjuvant brachytherapy. The survival and prognostic factors in the eligible and ineligible groups were analyzed. Overall, the patients eligible for brachytherapy (32% of the series) lived significantly longer than the ineligible patients (16.57 vs. 9.30 moaths), were younger, and had larger resections and better function. For giioblastoma, 40% of patients were eligible, and lived much longer than those who were ineligible (13.90 vs. 5.80 months). It is concluded that better outcome following adjuvant brachytherapy for glioma is at least in part the result of patient selection. Randomized trials of comparably selected patients will be necessary to demonstrate conclusively that longer survival is also a result of treatment.
I
NTERSTITIAL irradiation by means of stereotactically placed, removable, high-activity 125I sources is a promising treatment for patients with malignant (anaplastic) glioma of the cerebral hemispheres. Brachytherapy makes sense for cancers like glioma that kill by relentless local growth 5 and for which irradiation is the most effective treatment. During the 1980's, the technical aspects of brachytherapy for glioma were refined, long survival periods were observed after treatment of recurrent tumor, 23t~ and the toxic effects of treatment were carefully recorded and judged acceptable, s Interstitial irradiation, before or after external beam radiation, is now part of the initial treatment for patients with malignant glioma at many centers, and is being compared to standard treatment at some. 1'4'9 The following retrospective analysis of patients with supratentorial malignant glioma seen at a regional cancer center and treated conventionally was designed to answer two questions: what proportion of all patients would have been eligible for adjuvant brachytherapy, and did eligible patients live longer than ineligible ones?
Clinical Material and Methods
We identified all newly diagnosed adult patients (age _> 16 years)with biopsy-proven supratentorial malignant glioma treated at the London Regional Cancer Centre between January 1, 1988 , and December 31, 1989. To minimize possible bias introduced by the preselection of cases by referring doctors, we chose a center at which experience with malignant glioma is population-based. The London Regional Cancer Centre is a regional cancer treatment facility and the sole radiation therapy unit in central southwestern Ontario (population 1.1 million). It is a division of the provincial cancer network and is affiliated with the University of Western Ontario. Similarly, the University's Department of Clinical Neurological Sciences is the region's principal neurodiagnostic and neurosurgical unit. As a result of this organizational framework, virtually all patients in the region with malignant glioma are evaluated, treated, and followed by two neuro-oncologists.
We also chose a center where patients received standard initial treatment consisting of the maximum feasible surgical resection and external beam radiation therapy. Most patients also received adjuvant chemotherapy, either carmustine (1,3-bis(2-chloroethyl)-l-nitrosourea) or combination chemotherapy containing a nitrosourea. Treatment for progressive or recurrent tumor was individualized; five patients in the study group received interstitial irradiation. Adrenocorticosteroids (steroids) were used perioperatively, during the early stages of radiation, and as necessary thereafter. Steroids were not administered to prolong terminal situations. Financial considerations were not a barrier to diagnosis, treatment, or follow-up examination. From each patient's clinical record we recorded the date of diagnosis, patient age at diagnosis, tumor type (glioblastoma or anaplastic glioma), extent of resection as judged by the operative note (biopsy, partial resection, or gross total resection), Karnofsky Performance Scale (KPS) 6 status before and after surgery and after radiation therapy, and the date and cause of death. Preoperative and postoperative computerized tomography (CT) scans were compared and the degree of resection of the enhancing mass was defined as follows: biopsy, less than 25%; minor resection, 25% to 49%; major resection, 50% to 90%; and near-total resection, more than 90%. For nonenhancing malignant gliomas we estimated the extent of resection of the abnormal area.
Each patient's preoperative, postoperative, and postradiation therapy CT scans or magnetic resonance images were reviewed by three of the authors: two surgeons and a radiation oncologist familiar with interstitial irradiation. Independently, following established guidelines, ~' 2"4 and based on these imaging studies, they selected the implantable tumors. Tumors that were large (> 6 cm), diffuse, extending to the midiine or below the tentorium, spreading subependymally, or multifocal were considered not to be implantable. The reviewers were then given KPS scores for the implantable cases and asked to select those patients who would have been eligible for adjuvant brachytherapy. Again, following established guidelines, L.2.4,9 patients with poor function (KPS score < 70) were considered ineligible. Age alone was not used as a deciding factor.
After designating each patient as eligible or ineligible for adjuvant interstitial irradiation, we calculated the percentage of newly diagnosed patients for whom "upfront" brachytherapy was an option. Survival curves were generated for the eligible and ineligible groups using the product-limit method. 7 Patients alive on January 1, 1991, were censored, but four (one eligible and three ineligible) who died prematurely as a result of pulmonary embolism, were included. Median survival times were compared using the generalized Wilcoxon test (Breslow). 7 We also generated survival curves and R. C. Florell, et al. compared the median survival times for eligible and ineligible patients with glioblastoma and anaplastic glioma. Then, for all eligible and ineligible patients, and the subset with glioblastoma, we analyzed the distribution of three important prognostic factors: age, extent of resection, and KPS status before and after surgery and after radiation therapy. Mean age and mean KPS score were compared using Student's t-test. Analysis of covariance was used to compare changes in the KPS score following surgery and radiotherapy for the eligible and ineligible groups. Degrees of resection, estimated by operative notes and CT scans, were compared using the chi-squared test.
To further examine the prognostic importance of performance status, we selected patients with good neurological function (KPS score _> 70) and compared the median durations of survival of those with implantable versus nonimplantable tumors. Finally, we repeated the entire analysis excluding the five eligible patients who were implanted at recurrence.
Results
The 101 adults included 54 men and 47 women with supratentofial malignant glioma seen at the London Regional Cancer Centre over a period of 2 years. They ranged in age from 16 to 81 years (mean 54 years). The tumor was a glioblastoma in 68 cases and an anaplastic giioma in 33 (27 anaplastic astrocytoma, five anaplastic mixed glioma, and one anaplastic oligodendroglioma). Thirty-three patients had frontal tumors, 31 temporal, 18 parietal, three occipital, two thalamic, 11 bihemispheric or callosal, and three multifocal. The tumor was right-sided in 53 cases and left-sided in 35. The procedure was a biopsy in 23 cases, partial resection in 69, and gross total resection in nine based on the operative notes; judged by the CT scans, the procedure was a biopsy in 35 cases, minor resection in 15, major resection in 30, near-total resection in 20, and not evaluable in one (postoperative CT scan was missing). Eighty patients completed radiation therapy, two refused irradiation, 10 were not irradiated due to poor postoperative function, and radiation therapy was discontinued in nine deteriorating patients. The mean KPS score was 70.1 before surgery, 69.9 after surgery, and 70.5 in those completing the prescribed course of irradiation. The median duration of survival was 11.37 months (95% confidence interval, range 8.80 to 13.07 months) for all patients, 8.80 months (95% confidence interval range, 6.63 to 11.57 months) for those with glioblastoma, and 27.03 months (95% confidence interval, range 14.93 to 27.37 months) for those with anaplastic glioma.
The tumor was implantable in 43 patients (43%), but after excluding 10 with poor performance status scores and one who refused all treatment after surgery, only 32 (32%, 27 glioblastomas and five anaplastic gliomas) were eligible for adjuvant brachytherapy. Twenty-seven (40%) of the 68 patients with glioblastoma were eligible for brachytherapy, compared to five (15%) of the 33 with anaplastic glioma. Fifty-eight tumors (57%) were considered not to be implantable for the reasons outlined in Table 1 . The characteristics rendering them nonimplantable varied with the tumor type. It is of note that 44% of anaplastic gliomas were judged nonimplantable based on their large size and diffuse margins. Failure to enhance following intravenous infusion of contrast material contributed to the perception of diffuse margins in six patients with anaplastic glioma.
Patients eligible for brachytherapy lived for a median of 16.57 months (95% confidence interval, range 12.00 to 21.70 months). Ineligible patients lived a median of 9.30 months (95% confidence interval, range 5.80 to 11.57 months). This difference in median survival time was statistically significant (p = 0.004) (Fig. 1 left) .
Moreover, eligible patients were younger, had more extensive resections, and had better function than their ineligible counterparts (Table 2) . For example, neartotal resection was achieved in 45% of eligible patients as compared to 9% of ineligible ones. For glioblastoma, (Fig. 1   center) . Likewise, eligible patients were younger, had more extensive resections, and better function (Table  3 ). Significant differences in postoperative and postirradiation KPS scores between eligible and ineligible groups remained after correction for preoperative differences in performance status. Significant differences in the median survival period persisted after five patients with glioblastoma implanted at recurrence were excluded.
FIG. 1. Survival curves for 101 patients judged eligible or ineligible for adjuvant brachytherapy. Left:
Curves for all patients in the series. Center: Curves for 68 patients with glioblastoma multiforme. Right:
Curves for 33 patients with anaplastic glioma (malignant glioma other than glioblastoma). Classification of extent of resection as defined from postoperative neuroimaging.
w Mean score in 24 patients, excluding 17 who did not have, or did not complete, the prescribed radiation therapy.
For anaplastic glinma, the small numbers of patients eligible for brachytherapy made it difficult to calculate a median duration of survival: two patients died 18.53 and 27.03 months after implantation and three were alive and censored with a minimum follow-up period of 18 months. The same consideration also precluded meaningful comparison to the ineligible patients whose median survival period was 24.83 months (95% confidence interval, range 9.97 to 27.37 months) (Fig.  1 right) . Patients with implantable tumors and those with nonimplantable tumors but good performance status had similar median durations of survival: 16.30 versus 17.93 months (p = 0.41) for all patients; 13.73 versus 11.57 months (p = 0.15) for the subset with glioblastoma.
Discussion
This analysis demonstrates that only a minority of patients with malignant glioma are eligible for adjuvant brachytherapy, that eligible patients live considerably longer than ineligible ones by virtue of their younger age, larger tumor resections, and better performance status, and that performance status, more than tumor size or location, is the major determinant of survival time. The implications of this study are clear: 1) adjuvant brachytherapy, however effective, is not suitable for most patients with malignant giial tumors, ~,9 and 2) longer than expected survival periods following adjuvant brachytherapy 4.9 are at least in part the result of patient selection. Gutin, et al., 4 reported that patients with glioblastoma have a median survival period of 88 weeks following adjuvant brachytherapy, and Loeffler, et al.fl reported a median duration of survival in similarly treated patients in excess of 24 months. These groups of patients lived considerably longer than conventionally treated, brachytherapy-eligible patients with glioblastoma managed at the London Regional Cancer Centre. Presumably, their longer survival period is a measure of the benefit of adjuvant interstitial irradiation, but the groups were not identical. Compared to the brachytherapy-eligible patients with glioblastoma reported here, those implanted by Gutin, et are reminded from previous work 'j that study patients are a special subset of studyeligible patients and sometimes live longer. Second, the "process of referral" to special brain-tumor centers may inadvertently select a subset of brachytherapy-eligible patients with somewhat less aggressive tumors. Parenthetically, the conventionally treated, brachytherapyeligible patients with glioblastoma in this report and the patients with malignant glioma receiving adjuvant interstitial irradiation, reported by Bernstein, et al., ~ have similar median durations of survival (13.90 months vs. 60 weeks). Clearly, randomized trials of comparably selected patients will be necessary to demonstrate unequivocally that longer survival times following adjuvant brachytherapy are also an effect of treatment.
Two final points merit comment. First, a greater proportion of patients with glioblastoma than with anaplastic glioma were brachytherapy eligible (40% glioblastoma vs. 15% anaplastic glioma). It seems paradoxical that aggressive glioblastomas would be more amenable to local therapy than less aggressive anaplastic gliomas but, of course, intense enhancement gives most glioblastomas a discrete radiological appearance. Glioblastomas appear implantable, whereas anaplastie gliomas with their variable enhancement and typically diffuse margins do not. Gutin, et aI., 4 no longer recommend adjuvant interstitial irradiation for patients with anaplastic glioma because these patients live a long time following conventional treatment. Second, in the same way that long survival following brachytherapy is in part a function of patient selection, selection bias will undoubtedly contribute to longer than expected survival following other intensive local therapies for malignant glioma such as radiosurgery, intracarotid chemotherapy, intratumoral chemotherapy, photodynamic therapy, and regional immunotherapy.
